Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 8, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares and American Depositary Receipts (ADRs) of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details specific transactions executed on May 5, 2006, by the GlaxoSmithKline Employee Trust ("the GSK Trust") on behalf of plan participants:
- Ordinary Shares: The GSK Trust transferred 115,938 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- ADRs Sold: The GSK Trust sold 5,797 ADRs to participants in the SmithKline Beecham Mid-Term Incentive Plan at a price of $56.93 per ADR.
- ADRs Transferred: The GSK Trust transferred 12,058 ADRs to participants in the SmithKline Beecham Mid-Term Incentive Plan.
Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions.
Investor Verification Checklist
- Verify the total number of shares and ADRs distributed to employees under the SmithKline Beecham plans.
- Confirm the transaction price of $56.93 per ADR against market prices on May 5, 2006.
- Review the specific holdings of Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop within the GSK Trust.
- Ensure compliance with Disclosure Rule 3.1.4R(1)(b) regarding the notification of these connected person transactions.